Total Funding
60
36
Total FundingPost-IPO Equity raised
Growth Score
0 pts
Heat Score
5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
133420
Bellicum Pharmaceuticals is a clinical-stage biopharmaceutical company that is driving the future of cellular immuno-oncology (IO).
- Kevin Slawin: FounderPast Role: Memorial Hermann Health System, Director of Urology - MMH TMC
- Aaron Foster: Vice President of Product Discovery
About the Company
Bellicum Pharmaceuticals is a clinical stage company developing next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases. Bellicum's novel approach is to utilize precise knowledge of the signaling pathways that regulate the immune response to target specific factors
that can influence the potency and duration of this response.
